Congestive heart failure in children.
Although revitalizing dead or severely injured myocardial cells is still beyond the reach of modern treatment, the ability to change the loading conditions and the contractile state of the heart has enabled practitioners to reverse deleterious compensatory mechanisms in patients with CHF. Several new and improved medicines have made this strategy possible. Early and determined surgical treatment of patients with CHF has enabled cure of some previously debilitating or fatal defects. The combined use of surgery and interventional catheterization has allowed many patients to profit from the benefits not available from either modality alone. In the future, cellular, subcellular, and gene therapy may make the treatment of patients with CHF simple and even prevent CHD.
O'Laughlin
M P
MP
Pediatric Cardiovascular Program, Duke University Medical Center, Durham, North Carolina, USA.
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D006328:Cardiac Catheterization; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D016027:Heart Transplantation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010808:Physical Examination / Q000379:methods; D012017:Referral and Consultation; D012307:Risk Factors
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents